Steven Mah
Stock Analyst at TD Cowen
(n/a)
# 4,777
Out of 4,828 analysts
31
Total ratings
n/a
Success rate
-53.15%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $32.61 | +77.86% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $22.36 | +38.64% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $7.87 | +1,424.78% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $4.39 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $23.88 | +75.88% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $2.01 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.56 | +543.09% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.80 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.46 | +753.66% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $162.57 | -4.66% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.14 | +2,356.14% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $18.56 | +654.31% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.20 | +4,233.33% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $79.58 | +421.49% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $80 | $2.87 | +2,692.32% | 1 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $36.46 | +585.68% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $32.61
Upside: +77.86%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $22.36
Upside: +38.64%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $7.87
Upside: +1,424.78%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $4.39
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $23.88
Upside: +75.88%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.01
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.56
Upside: +543.09%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.80
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.46
Upside: +753.66%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $162.57
Upside: -4.66%
May 11, 2021
Initiates: Overweight
Price Target: $28
Current: $1.14
Upside: +2,356.14%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $18.56
Upside: +654.31%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.20
Upside: +4,233.33%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $79.58
Upside: +421.49%
Dec 16, 2020
Upgrades: Overweight
Price Target: $40 → $80
Current: $2.87
Upside: +2,692.32%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $36.46
Upside: +585.68%